Singapore Eye Research Institute, Singapore, Singapore.
Singapore National Eye Centre, Singapore, Singapore.
Sci Rep. 2020 Jan 28;10(1):1341. doi: 10.1038/s41598-020-58346-3.
Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the current standard of treatment for choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD), but there are no diagnostic tools to predict response of these therapies. We hypothesize that differences in baseline metabolic profiles of patients with nAMD may influence responsiveness to anti-VEGF therapy, and thus provide prognosticating information for these patients. A prospective study was performed on 100 patients with nAMD treated with anti-VEGF therapy. We classified patients into two groups: responders (n = 54) and non-responders (n = 46). The expression levels of glycerophosphocholine,LysoPC (18:2) and PS (18:0/20:4) were higher in non-responders and these findings were verified in the validation cohort, implicating that reductions in these three metabolites can be used as predictors for responsiveness to anti-VEGF therapy during the initial loading phase for patients with nAMD. Our study also provided new insights into the pathophysiological changes and molecular mechanism of anti- VEGF therapy for nAMD patients.
玻璃体内注射抗血管内皮生长因子（anti-VEGF）是治疗新生血管性年龄相关性黄斑变性（nAMD）继发脉络膜新生血管（CNV）的目前标准治疗方法，但目前还没有诊断工具来预测这些治疗的反应。我们假设 nAMD 患者的基线代谢特征的差异可能会影响对抗 VEGF 治疗的反应，从而为这些患者提供预后信息。我们对 100 名接受抗 VEGF 治疗的 nAMD 患者进行了前瞻性研究。我们将患者分为两组：应答者（n=54）和无应答者（n=46）。无应答者的甘油磷酸胆碱、溶血磷脂酰胆碱（18:2）和 PS（18:0/20:4）的表达水平较高，这些发现在验证队列中得到了验证，表明在 nAMD 患者的初始负荷期，这三种代谢物的减少可以用作对抗 VEGF 治疗反应的预测因子。我们的研究还为 nAMD 患者抗 VEGF 治疗的病理生理变化和分子机制提供了新的见解。
